secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001213900-25-029639
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix signs LOI for business combination with Ocuvex; Ocuvex holders to own ~90%
--------------------------------------------------------------------------------

- Non-binding LOI with Ocuvex Therapeutics, a private ophthalmic biopharma company with FDA-approved product and late-stage clinical assets.
- Upon closing, Onconetix will issue new shares to acquire all Ocuvex equity; Ocuvex holders to own ~90% of combined company.
- Transaction subject to due diligence, definitive agreement, financing, regulatory and stockholder approvals; no assurance of completion.
- Onconetix Chairman Andrew J. Oakley states combination will 'immediately expand our reach beyond oncology, enhancing shareholder value.'
- Ocuvex President/CEO Anthony W. Amato notes combining will 'broaden access to capital.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/0001213900-25-029639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/ea0237471-8k_oncon.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-029639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer